africa-studio-shutterstock-com-2
Africa Studio / Shutterstock.com
2 September 2015Americas

Sequenom’s en banc bid boosted by support from US professors

A group of 23 law professors has urged the US Court of Appeals for the Federal Circuit to re-hear the Ariosa v Sequenom dispute en banc.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
19 August 2015   Sequenom has requested an en banc review of the US Court of Appeals for the Federal Circuit’s decision to invalidate one of its patents in its dispute with Ariosa Diagnostics, arguing that the decision creates an “existential threat” to patent protection.
Americas
17 June 2015   A US appeals court has affirmed that a patent covering the method of detecting foetal abnormalities in pregnant mothers is ineligible for protection because it applies to a “natural phenomenon”.

More on this story

Americas
19 August 2015   Sequenom has requested an en banc review of the US Court of Appeals for the Federal Circuit’s decision to invalidate one of its patents in its dispute with Ariosa Diagnostics, arguing that the decision creates an “existential threat” to patent protection.
Americas
17 June 2015   A US appeals court has affirmed that a patent covering the method of detecting foetal abnormalities in pregnant mothers is ineligible for protection because it applies to a “natural phenomenon”.

More on this story

Americas
19 August 2015   Sequenom has requested an en banc review of the US Court of Appeals for the Federal Circuit’s decision to invalidate one of its patents in its dispute with Ariosa Diagnostics, arguing that the decision creates an “existential threat” to patent protection.
Americas
17 June 2015   A US appeals court has affirmed that a patent covering the method of detecting foetal abnormalities in pregnant mothers is ineligible for protection because it applies to a “natural phenomenon”.